Skip to main content
. Author manuscript; available in PMC: 2022 Dec 2.
Published in final edited form as: Gastro Hep Adv. 2022 Jun 17;1(6):1014–1026. doi: 10.1016/j.gastha.2022.06.008

Table 3.

Total and Per Patient Follow-Up (f/u) Time, Number, and Incidence Rate of PDAC per 1000 Person-Years (PY) and 95% Confidence Interval (CI)

Patient characteristics Total f/u
time (y)
Average f/u
time (y)
No. of
PDAC
events
Incidence rate of
PDAC/1000 PY
(95% CI)
Time to PDAC
(days) (median, IQR)
All 88,550 1.9 370 4.2 (3.8, 4.6) 96 (49, 294)
Age group
 18–49 10,491 2.0 13 1.2 (0.7, 2.1) 56 (40, 64)
 50–59 15,124 2.1 49 3.2 (2.4, 4.3) 75 (46, 240)
 60–69 24,610 2.0 102 4.1 (3.4, 5.0) 83 (45, 235)
 70–79 28,882 2.0 153 5.3 (4.5, 6.2) 127 (57, 348)
 80–84 9443 1.4 53 5.6 (4.3, 7.4) 123 (45, 325)
Sex
 Female 50,083 1.9 168 3.4 (2.9, 3.9) 103 (57, 319)
 Male 38,467 1.9 202 5.3 (4.6, 6.0) 93 (42, 267)
Race/ethnicity
 Non-Hispanic White 45,531 1.9 182 4.0 (3.5, 4.6) 121 (52, 295)
 African American 10,134 2.0 60 5.9 (4.6, 7.6) 82 (47, 141)
 Hispanic 23,639 1.9 93 3.9 (3.2, 4.8) 107 (49, 403)
 Asian/Pacific Islanders 8303 2.0 34 4.1 (2.9, 5.7) 65 (40, 118)
 Unknown 943 1.7 1 1.1 (0.1, 7.5) 142 (142, 142)
Weight change in 1 y (kg)
 ≤−6 kg 11,806 1.7 118 10.0 (8.3, 12.0) 89 (44, 267)
 >−6 and ≤−4 kg 6989 1.9 43 6.2 (4.6, 8.3) 78 (37, 232)
 >−4 and ≤−2 kg 10,588 1.9 43 4.1 (3.0, 5.5) 141 (66, 454)
 >−2 and <2 kg 28,663 2.0 85 3.0 (2.4, 3.7) 103 (57, 274)
 ≥2 and <4 kg 7515 2.0 17 2.3 (1.4, 3.6) 132 (67, 308)
 ≥4 kg 8406 1.9 16 1.9 (1.2, 3.1) 122 (68, 559)
 Unknown 14,582 2.0 48 3.3 (2.5, 4.4) 67.5 (46, 137)
Family history of pancreatic cancer
 No 85,761 1.9 339 4.0 (3.6, 4.4) 94 (48, 286)
 Yes 2789 1.9 31 11.1 (7.8, 15.8) 150 (53, 336)
Imaging features
 Single
  Calcification only 19,363 2.1 22 1.1 (0.7, 1.7) 131 (56, 412)
  Duct dilatation only 13,307 2.0 110 8.3 (6.8, 10.0) 74 (42, 166)
  Atrophy only 19,711 1.8 32 1.6 (1.1, 2.3) 249 (61, 518)
  Cyst only 18,377 2.0 41 2.2 (1.6, 3.0) 120 (54, 333)
  Pseudocyst only 3315 2.0 10 3.0 (1.6, 5.6) 117 (62, 229)
 Two or more
  Calcification + duct dilatation (w/ or wo/ atrophy, cyst, pseudocyst) 2193 1.8 27 12.3 (8.4, 18.0) 99 (44, 454)
  Calcification + any 1 or more of (atrophy, cyst or pseudocyst) 3695 1.8 8 2.2 (1.1,4.3) 297 (125, 519)
  Duct dilatation + any 1 or more of (atrophy, cyst or pseudocyst) 3952 1.6 99 25.1 (20.5, 30.6) 78 (43, 204)
  Any 2 or more of (atrophy, cyst, pseudocyst) 4636 2.1 21 4.5 (3.0, 7.0) 294 (69, 530)
ALP values at baseline
 ≤125 53,696 1.9 193 3.6 (3.1, 4.1) 118 (56, 307)
 >125 7610 1.7 117 15.4 (12.8, 18.5) 68 (43, 145)
 Unknown 27,244 2.0 60 2.2 (1.7, 2.8) 120 (46, 446)
Lipase values at baseline
 <60 35,442 1.8 139 3.9 (3.3, 4.6) 102 (49, 333)
 [60, 180] 4422 1.8 48 10.9 (8.2, 14.4) 69 (41, 250)
 ≥180 2561 1.9 55 21.5 (16.4, 28.1) 91 (52, 178)
 Unknown 46,125 2.0 128 2.8 (2.3, 3.3) 112 (49, 345)
Total bilirubin values at baseline
 ≤1 46,501 1.9 179 3.8 (3.3, 4.5) 111 (56, 279)
 >1 14,901 1.8 129 8.7 (7.3, 10.3) 71 (44, 232)
 Unknown 27,148 2.1 62 2.3 (1.8, 2.9) 103 (44, 438)
HbA1c values at baseline
 <6.5% 30,601 1.8 113 3.7 (3.1, 4.4) 107 (52, 342)
 6.5%–6.9% 6745 1.9 33 4.9 (3.5, 6.9) 76 (41, 200)
 7%–7.4% 4680 1.9 26 5.6 (3.8, 8.2) 79 (43, 294)
 ≥7.5% 9956 1.8 78 7.8 (6.3, 9.8) 103(54, 317)
 Unknown 36,567 2.1 120 3.3 (2.7, 3.9) 97 (48.5, 269.5)
ALT change within 1 y prior
 <−5 8322 1.9 28 3.4 (2.3, 4.9) 147 (66, 344)
 [−5, 5] 20,194 2.0 69 3.4 (2.7, 4.3) 146 (54, 357)
 ≥5 11,351 1.9 78 6.9 (5.5, 8.6) 73 (40, 182)
 Unknown 48,683 1.9 195 4.0 (3.5, 4.6) 94 (52, 295)
Abdominal pain within 6 mo
 No 58,503 1.9 195 3.3 (2.9, 3.8) 143 (57, 403)
 Yes 30,047 1.9 175 5.8 (5.0, 6.8) 75 (43, 190)
Dyspepsia within 6 mo
 No 85,695 1.9 345 4.0 (3.6, 4.5) 102 (49, 300)
 Yes 2855 2.0 25 8.8 (5.9, 13.0) 59 (44, 163)
Malaise/fatigue
 No 40,301 2.0 186 4.6 (4.0, 5.3) 87 (48, 294)
 Yes 48,249 1.8 184 3.8 (3.3, 4.4) 103 (50, 290)
Weight loss
 No 66,058 2.0 244 3.7 (3.3, 4.2) 93 (52, 285)
 Yes 22,492 1.8 126 5.6 (4.7, 6.7) 110 (45, 307)

ALP, alkaline phosphatase; ALT, Alanine transaminase.